We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Radient Pharmaceuticals Presented Two Abstracts at Gastrointestinal Cancers Symposium

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

These abstracts are now available for viewing at ASCO.org and will be published in the 4th Supplement of Journal of Clinical Oncology in February 2012.

The conference was held on January 19-21, 2012 at the Moscone West Building in San Francisco, California. Dr. Afsaneh Motamed-Khorasani, the Director of Oncology at Radient Pharmaceuticals, presented the data in the two abstracts.

These abstracts were the results of a collaborative study in the United States that compared the combined use of Onko-Sure® with Carcinoembryonic Antigen (CEA), the routine blood biomarker for Colorectal Cancer (CRC), versus CEA alone. The clinical study included a total of 639 subjects. Radient Pharmaceuticals' proprietary Onko-Sure® cancer blood test combined with the CEA test were more effective for the detection of colorectal cancer compared to using the CEA test alone (an increase of 55% in the test sensitivity). Furthermore, the combined usage of Onko-Sure® and CEA in monitoring CRC recurrence showed a significant clinical advantage in terms of sensitivity (an increase of 35% in the test sensitivity compared to what CEA can provide).

The first abstract, entitled "A novel, cost-effective strategy for the screening of colorectal cancer with higher patience compliance" is available at the following link: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=115&abstractID=88133 . This study with 564 patients concluded that combining the Onko-Sure® cancer test and the CEA test for CRC screening shows a significant clinical advantage and this approach should improve the early stage diagnosis of CRC.

The second abstract is entitled "A new strategy for the early detection of colorectal cancer recurrence" and is available at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=115&abstractID=88123 . This study with 75 patients concluded that the combined usage of the Onko-Sure® cancer test and CEA in monitoring of the CRC recurrence also shows a significant clinical advantage. Dr. Motamed-Khorasani concludes that "improvements observed in this study by this companion diagnostic approach combining CEA and DR-70 raises a strong potential for the utility of this combined test for screening of high risk patients for colorectal cancer specially in stages I and II where early diagnosis can make a big difference. The sensitivity of 58% is well acceptable for a simple, non-expensive blood test with high patient compliance as a screening test while CEA with 38% sensitivity cannot be used for screening. Furthermore, the sensitivity of this combined test for detection of CRC recurrences was at 75% in comparison to what CEA can offer (56%). The early detection of recurrence has important effects on patient treatment options and survival rate."

"A key element of our 2012 strategy is to share our findings with influential groups of specialists, such as the attendees in ASCO Conference. There were close to 3,000 attendees in this conference and we are pleased by the reception we received," said Douglas MacLellan, Chairman and CEO. "Our Onko-Sure® colorectal cancer test provides a simple, non-expensive test that is not only effective and cleared for the monitoring of CRC but in combination with other diagnostic markers (CEA) could be potentially used for screening of the high risk individuals for CRC. This will potentially reduce the number of hospitalizations and annual deaths due to CRC."